KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026)

Aquestive Therapeutics has reported Cash from Investing Activities over the past 9 years, most recently at -$85000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 466.67% year-over-year to -$85000.0; the TTM value through Dec 2025 reached -$562000.0, down 253.46%, while the annual FY2025 figure was -$562000.0, 253.46% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$85000.0 at Aquestive Therapeutics, up from -$235000.0 in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at -$2000.0 in Q1 2023 and troughed at -$1.7 million in Q3 2022.
  • A 5-year average of -$257650.0 and a median of -$103500.0 in 2021 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 1968.67% in 2022 and later soared 98.08% in 2023.
  • Year by year, Cash from Investing Activities stood at -$533000.0 in 2021, then surged by 95.12% to -$26000.0 in 2022, then surged by 38.46% to -$16000.0 in 2023, then increased by 6.25% to -$15000.0 in 2024, then tumbled by 466.67% to -$85000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for AQST at -$85000.0 in Q4 2025, -$235000.0 in Q3 2025, and -$107000.0 in Q2 2025.